RYTM
What one share of Rhythm Pharmaceuticals holds
Pharmaceutical Preparations
We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.
Rhythm Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.56 |
|---|---|
| Profit | −$3.12 |
| Cash and investments | $0.95 |
| Debt | $1.54 |
| Book value | $1.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$2.85 | $0.10 | −$2.38 | — | −$3.21 |
| 2017 | $0.00 | −$2.83 | $0.01 | −$2.23 | — | — |
| 2018 | $0.00 | −$2.39 | $0.02 | −$2.02 | — | $7.16 |
| 2019 | $0.00 | −$3.86 | $0.09 | −$3.46 | — | $6.39 |
| 2020 | $0.00 | −$3.04 | $0.00 | −$2.77 | — | $3.76 |
| 2021 | $0.06 | −$1.40 | $0.01 | −$2.95 | — | $5.65 |
| 2022 | $0.45 | −$3.48 | $0.01 | −$3.33 | — | $4.67 |
| 2023 | $1.34 | −$3.20 | $0.00 | −$2.36 | — | $2.86 |
| 2024 | $2.13 | −$4.34 | $0.00 | −$1.87 | — | $0.35 |
| 2025 | $2.92 | −$3.11 | $0.01 | −$1.79 | — | $2.07 |